期刊文献+

加减补中益气汤联合奥沙利铂、替吉奥方案治疗晚期胃癌随机对照临床研究 被引量:7

Clinical Observation of Buzhong Yiqi Decoction Combined with SOX Therapy on the Patient with Advanced Gastric Cancer
下载PDF
导出
摘要 [目的]观察加减补中益气汤联合奥沙利铂、替吉奥(SOX)方案治疗晚期胃癌患者的临床疗效。[方法]采用随机、对照方法。将53例晚期胃癌患者随机分为两组,对照组26例采用SOX方案化疗,治疗组27例在对照组治疗的基础上同时口服加减补中益气汤,自化疗前3d开始服用,1剂/d,分2次温服,连续服用至化疗结束后3d。两组均以21d为1周期,完成2个周期后评价近期疗效、中医证候疗效、毒副反应等。[结果]两组近期疗效总有效率比较无明显差异(P>0.05)。在中医证候疗效、体力状况疗效方面,治疗组治疗后指标优于对照组(P<0.01);治疗组的白细胞减少、消化道反应、周围神经毒性程度优于对照组(P<0.05)。[结论]加减补中益气汤联合SOX方案治疗晚期胃癌可以改善患者的中医症候及体力状况,降低化疗毒副反应,优于单纯SOX方案化疗。 [Objective]Observing the impact of Buzhong Yiqi Decoction Combined with SOX(L-OHP、S1) therapy on the patient with Advanced Gastric Cancer.[Methods]53 cases with advanced gastric cancer randomly divied into two groups.26 cases of control were treated only with SOX program.On this basis,27 cases of treatment group were treated with SOX program plus Buzhong Yiqi decoction and took Buzhong Yiqi decoction 3 days before chemotherapy,one dose daily,twice a day,until 3 days after chemotherapy finished.Two groups regard 21days as a course of treatment.Observing the short term effect,clinical symptom,toxicity of the two groups after 2 cycles.[Results]On the short term effect,there is no significant difference between the two groups(P0.05);On clinical symptom,physical condition,the index of treatment group after treatment was better than that of control group(P0.01);neutropenia,gastrointestinal reactions and the toxicity of peripheral nerve of treatment group were lower than of control group(P0.05).[Conclusion]Buzhong Yiqi decoction combined with SOX(L-OHP、S1) therapy can improve the clinical symptom and physical condition,alleviate the toxicity of chemotherapy.It is better than SOX therapy.
作者 秦晓纲
出处 《实用中医内科杂志》 2012年第10期39-41,共3页 Journal of Practical Traditional Chinese Internal Medicine
关键词 胃肿瘤 补中益气汤 SOX方案 奥沙利铂 替吉奥 临床研究 随机对照 Gastric tumor Buzhong Yiqi decoction SOX chemotherapy Oxaliplatin S1 Clinical observation Random control
  • 相关文献

参考文献6

二级参考文献31

  • 1钱军,秦叔逵,梅静峰,陈映霞,邵志坚,何泽明.奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察[J].中华肿瘤杂志,2004,26(12):746-748. 被引量:60
  • 2黄河,管忠震,秦凤展,张燕军,黎莉,高亚杰,王顺金,顾康生,郭颖,孙飘扬.左亚叶酸钙联合5-氟尿嘧啶、奥沙利铂治疗晚期或复发胃、结直肠癌的Ⅱ期临床研究[J].广东医学,2005,26(11):1568-1570. 被引量:10
  • 3Cunningham D,Allum WH,Stenning SP,菅鑫妍.手术期间化学疗法与单独手术治疗可切除的胃食管癌疗效比较[J].中国处方药,2006,5(8):59-60. 被引量:434
  • 4Malet-Martino M,Martino R.Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine,UFT,S-1):a review[J].Oncologist,2002,7(4):288-323.
  • 5Tanaka F,Fukuse T,Wada H,et al.The history,mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents[J].Curr Pharm Biotechnol,2000,1(2):137-164.
  • 6Shirasaka T,Shimamato Y,Ohshimo H,et al.Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators[J].Anticancer Drugs,1996,7(5):548-557.
  • 7Shirasaka T,Tsukuda M,Inuyama Y,et al.New oral anticancer drug,TS-1 (S-1)-from bench to clinic[J].Gan To Kagaku Ryoho,2001,28(6):855-864.
  • 8Sato A,Ito T,Tomita T,et al.Chemotherapy of gastric cancer--a review of clinical trials in Japan[J].Gan To Kagaku Ryoho,2002,29(9):1522-1531.
  • 9Moiseyenko VM,Ajani JA,Tjulandin SA,et al.Final results of a randomized controlled phase Ⅲ trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F)to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2005,23:Abstract 4002.
  • 10Al-Batran S,Hartmann J,Probst S,et al.A randomized phase Ⅲ trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil,leucovorin and oxaliplatin (FLO) versus fluorouracil,leucovorin and cisplatin (FLP)[J].J Clin Onc,Proc Am Soc Clin Oncol,2006,24:Abstract 4016.

共引文献352

同被引文献162

引证文献7

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部